Quote:

---

NIH just announced 3 studies to investigate Long Covid treatments.

---

Quote:

---

The two trials, collectively known as RECOVER-AUTONOMIC, are testing three potential treatments in adults who, following COVID-19, now have postural orthostatic tachycardia syndrome (POTS). An autonomic nervous system disorder, POTS is characterized by unexpected fast heart rate, dizziness, fatigue or a combination of these symptoms when a person stands up from sitting or lying down.

The trials will initially examine three potential treatments:

Gamunex-C, a form of intravenous immunoglobulin (IVIG), contains antibodies to help the body protect itself against infection from various diseases and is given by intravenous infusion.
Ivabradine, an oral medication that reduces heart rate.
Coordinator-guided, non-drug care, which includes a series of activities managed through weekly phone calls with a care coordinator, such as wearing a compression belt and eating a high-salt diet, which are recommended for patients with POTS to counteract excessive loss of fluids.
https://www.nih.gov/news-events/news-releases...ysfunction

---

Oy Vey! They are certainly adverse to looking at the big picture. They are so puzzled by Long Covid that they're going after it symptom by symptom. With the wide array of symptoms is their goal to treat patients with a dozen drugs at a time? That will certainly present drug interaction problems. It's a time and money wasting approach.

With the large amount of research out there they should know that immune dysregulation and inflammation are the driving cause of symptoms. You would think they would look at drugs that have shown promise, especially in preliminary trials like leronlimab.